Harvey MJ, Zhong Y, Morris E, Beverage JN, et al. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma. PLoS One 2022;17:e0261336.
PMID: 35073335